Dr.Mirallas

🚀 just published @sitcancer.bsky.social #JITC

👥 34,973 pts
♻️ 47 #RCT
💉 PD-1 the earlier the better
HR=0.74
📌 #PFS2 great correlation to #OS
R² 0.74 #PFS2 vs 0.39 #PFS

Led by Dr. Jimenez-Labaig

@oncoalert.bsky.social @brunolarvol.bsky.social @vhio.bsky.social
👇🏽
jitc.bmj.com/content/jitc/1…

01.12.2025 01:38 — 👍 1    🔁 1    💬 0    📌 0

Moltes felicitats!!

17.09.2025 22:57 — 👍 1    🔁 0    💬 0    📌 0

#NIH did this. We fund medical research to help burn patients and benefit them and all Americans.

17.09.2025 20:24 — 👍 65    🔁 20    💬 0    📌 1

💥 Practice changing #SCLC ❗

📌 DeLLphi-304
Tarlatamab vs ChT 2L ED SCLC

✅ mOS 13.6 vs 8.3m
✅ mPFS 5.3 vs 4.3m
✅ ORR 35 vs 20%
☣️ =>G3 54 vs 80%
⚠️ Watch #CRS 56% and #ICAN for Tarla
🧠 45% brain M1

@oncoalert.bsky.social
@ascocancer.bsky.social
@myesmo.bsky.social
#OncoAlertAF

✍🏽 June 2👇🏽

14.06.2025 10:40 — 👍 2    🔁 2    💬 0    📌 0

#ASCO25

🔥 MATTERNHORN: adding #Durvalumab to FLOT GEJ/GC ADK resectable

🗣️ Dr. Janjigian

✅ DFS 67 vs 57% at 24m HR 0.71
✅ mOS 76 vs 70% at 24m
✅ pCR 19 vs 7%
90% PD-L1+

#OncoNexion25
@oncoalert.bsky.social
@ascocancer.bsky.social @vhio.bsky.social
@myesmo.bsky.social

01.06.2025 21:47 — 👍 4    🔁 1    💬 0    📌 0

#ASCO25

Drug development track 🔥

IZA-BREN/BL-B01D1

💉 EGFR-HER3 bispecific ADC (TOP I) #NSCLC
☣️ Hematological
☣️ 1 ILD G2, no deaths

✅ORR 45.6%
✅ Exon 20ins: 85%, HERm: 61.5%
✅ SCLC ORR 75%!

#OncoNexion25 @oncoalert.bsky.social
@myesmo.bsky.social @ascocancer.bsky.social
@vhio.bsky.social

30.05.2025 20:29 — 👍 4    🔁 2    💬 0    📌 0

#ASCO2025

🔥 Drug development track
🕑 2:45pm

📉 Exciting science to be presented❗

New drugs into #trials
💉 Biespecific+/- ADC
💥 ADC+ IO
🎯 #KRASG12D
🧬 New small mol #KIF18A
🩸⚒️ More #ctDNA and new #IA

@oncoalert.bsky.social
@myesmo.bsky.social

👇🏽 My TOP 10 for #drugdevelopment

30.05.2025 19:06 — 👍 0    🔁 0    💬 0    📌 0

🤩 Exciting news !!

Great work led by Dr. Galip and Sütcüoglu #Turkey

📌 Impressive results of #PROMISE outside Spain
✅ Better mortality prediction over #GRm and #CTI
⬆️Risk OR 3.32 vs 2.85 vs 1.83
⬇️Risk OR 0.22 vs 0.35 vs 0.73

💥AUC promise 0.868!!

🙌🏽 Combined with CTI: AUC 0.884

Find more👇🏽

09.05.2025 23:21 — 👍 0    🔁 0    💬 0    📌 0

Ready to start the EACR Conference_Persister Cells: from Bacteria to Cancer in Lyon!!!
@helloeacr.bsky.social @vhio.bsky.social

18.03.2025 12:38 — 👍 6    🔁 2    💬 0    📌 0

📢 It has been a learning experience over the past 3 days at #ESMOTAT25 to listen to experts in the field of #phaseI #drugdevelopment

🗣️ The talks were truly insightful
✅ New and improved drugs 🎯
📊 Innovative trial designs

@myesmo.bsky.social
@viveksubbiah.bsky.social
@oncoalert.bsky.social

05.03.2025 18:45 — 👍 4    🔁 2    💬 0    📌 0

Thanks #ESMOTAT25 & #ESMOYOC for the kind invitation to speak alongside #TeamManchester colleague Dr André Freitas - AI/ML 👨‍💻 expert @cruk-mi.bsky.social.

We discussed tips & tricks + pitfalls of using (generative) AI 🤖 for paper and grant writing.

@uom-dcs.bsky.social
@mcrcnews.bsky.social

04.03.2025 16:56 — 👍 11    🔁 3    💬 1    📌 0

#ESMOTAT25
🔥 Starting the day with #AI tools and it's application to #science and writing grants/papers

✅ Helping in style and format
✅ Prompts very important
❌ Plagiarism, repetition, bad for searching

Great talks by @drjonlim.bsky.social Dr Freitas
#YOC @myesmo.bsky.social @vhio.bsky.social

04.03.2025 07:52 — 👍 6    🔁 2    💬 1    📌 1

¿A punto de elegir tu especialidad #MIR? ¡Este evento es para ti ‼️

💬 Te contamos todo sobre #OncologíaMédica en @vallhebroncampus.bsky.social: nuestro programa, oportunidades y resolvemos tus dudas en solo 30 min.

📅 21/02 | ⏰ 11:00 h ℹ️ https://linke.to/PostMir25

#ResisOncoVH

14.02.2025 18:04 — 👍 1    🔁 1    💬 0    📌 0

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - Nature Medicine As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF inhibitor encorafenib,...

🚀 Encorafenib&Cetuximab + mFOLFOX6 vs #CT choice

#BREAKWATER P3 for #CRC with BRAF V600E mut

💊💊+💉
👉🏽 ORR 60.9%
👉🏽 mOS NE
☣️ G3/4 74%

💉
👉🏽 ORR 40%
👉🏽 mOS 14.6m
☣️ G3/4 61%

✅ Met ORR #primary endpoint
❌ OS just yet

@natmedicine.bsky.social
@vhio.bsky.social

www.nature.com/articles/s41...

03.02.2025 18:36 — 👍 1    🔁 0    💬 0    📌 0

📢 Less than 6 hrs until @ASCO #abstractsubmission ❗

⚠️ Deadline ⚠️

🕕 6am Europe #Spain time
🕛 11:59pm EST

#ASCO25

❤️‍🔥Burning midnight here in Europe 🇪🇺

🏃🏽‍♂️ #FinishTheJob

🙌🏽 Hope to see you all in Chicago

@vhio.bsky.social @ascocancer.bsky.social @oncoalert.bsky.social @vallhebroncampus.bsky.social

28.01.2025 23:36 — 👍 7    🔁 2    💬 0    📌 0